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Abstract
Exfoliation syndrome (XFS) is the commonest recognizable cause of open angle glaucoma world-
wide. To better understand the etiology of XFS, we conducted a genome-wide association study 
(GWAS) on 1,484 patients and 1,188 controls from Japan, and followed up the most significant 
findings on a further 6,901 patients and 20,727 controls from 17 countries across 6 continents. We 
discovered a significant association between a new locus (CACNA1A rs4926244) and increased 
susceptibility to XFS (Odds ratio [OR] = 1.16, P = 3.36 × 10−11). Although overwhelming 
association at the LOXL1 locus was confirmed, the key SNP marker (LOXL1 rs4886776) 
demonstrated allelic reversal depending on ethnic grouping (In Japanese: ORA-allele= 9.87, P = 
2.13 × 10−217; In non-Japanese: ORA-allele= 0.49, P = 2.35 × 10−31). Our findings represent the 
first genetic locus outside of LOXL1 which surpasses genome-wide significance for XFS, and 
provides insight into the biology and pathogenesis of the disease.
XFS is a generalized disorder of the extracellular matrix that manifests most conspicuously 
in the eye. The exfoliation material consists of cross-linked, amyloid-like fibrillar material 
and glycoproteins. Apart from ocular tissues, this material deposits around blood vessels 
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particularly in association with elastic connective tissue, and could be found in other 
organs1. The build-up of exfoliation material deposits and pigment in the trabecular 
meshwork can damage this tissue and impede the drainage of aqueous humor from the eye 
thus resulting in elevated intraocular pressure and glaucomatous optic neuropathy. 
Exfoliation glaucoma is the most serious known complication of XFS2.
The first GWAS on XFS was reported in 2007 and successfully identified LOXL1 as a major 
susceptibility locus for XFS3. Since then, multiple studies have uniformly corroborated the 
association of genetic variants of LOXL1 with XFS4–21. However, data from these studies 
showed associated alleles for LOXL1 SNPs frequently undergo allelic reversal depending on 
ethnic group22. These findings suggest that complex genetic mechanisms are present for 
XFS pathogenesis, and the possibility that additional susceptibility loci for XFS remain to be 
identified. We assembled an international, multi-institutional collaborative effort across 6 
continents comprising 17 countries to conduct a GWAS discovery and two-staged 
replication study of XFS (see Methods, Supplementary Table 1, and Supplementary Figure 
1). Participating subjects provided written informed consent under the oversight of all local 
institutional review boards in accordance with the tenets of the Declaration of Helsinki.
For the GWAS discovery stage, we genotyped 717,991 SNP markers on 1,578 Japanese 
patients with XFS and 1,215 controls using the Illumina OmniExpress microarray. Control 
subjects were drawn from the same hospital where the XFS patients were first identified. A 
total of 1,484 cases and 1,188 controls passed quality control (QC) filters for call-rate, 
relatedness, heterozygosity and ancestry (see Methods for QC details) and were included for 
downstream association analysis. Multiple markers in strong linkage disequilibrium (LD) at 
the LOXL1 locus showed strong evidence of association with XFS (Supplementary Figure 
2a), with rs4886776 (P = 7.37 × 10−137) serving as the sentinel SNP.
A total of 66 SNPs outside of LOXL1 showed evidence of association with XFS surpassing 
P < 1 × 10−4 at the GWAS discovery stage. We thus designed validation assays for these 66 
SNP markers, together with LOXL1 rs4886776, and genotyped them in a follow up 
collection of 2,628 XFS cases and 8,947 controls drawn from 9 countries (Stage 1 
validation, see Supplementary Table 1). For each SNP examined, we conducted a fixed-
effects meta-analysis to summarize the observations across the nine studies. One SNP 
marker (rs4926244), mapping within the CACNA1A gene that showed association in the 
GWAS discovery stage at P = 5.50 × 10−5 (ORG-allele = 1.29) was also significant in this 
validation stage (ORG-allele = 1.17, P = 4.17 × 10−5). Thus for rs4926244, meta-analysis of 
both the discovery and validation stages revealed genome-wide significant association 
(ORG-allele = 1.20, P = 2.45 × 10−8) (Figure 1, Supplementary Table 2, and Supplementary 
Figure 2b). Results for all 67 SNP markers from the GWAS discovery and Stage 1 
replication are appended in Supplementary Table 2. We did not observe consistent evidence 
of association at CNTNAP2, a locus previously reported to associate with XFS from a 
pooled GWAS study23, as well as other previously reported candidate genes (Supplementary 
Table 3).
We subjected CACNA1A rs4926244 to further technical scrutiny in a third, independent 
dataset consisting of 4,273 XFS cases and 11,780 controls drawn from 8 additional countries 
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(Stage 2, replication; see Supplementary Table 1). The association maintained significance, 
consistent with findings observed in the two previous stages (ORG-allele = 1.13, P = 1.14 × 
10−4). Together, the combined discovery and two-stage replication patient collections 
consisting of 8,385 XFS cases and 21,915 controls provide evidence for association between 
the minor G allele at rs4926244 and XFS (P = 3.36 × 10−11). These data suggest risk for 
XFS increases approximately 1.16 fold for each copy of the minor G allele (Figure 1 and 
Supplementary Table 4). This association appears to be consistent with minimal 
heterogeneity when stratified for Asian (ORG-allele = 1.14, P = 7.46×10−6), European 
(ORG-allele=1.19, P=1.90×10−6) or South African (ORG-allele = 1.33, P = 0.11)(Phet = 0.5, I2 
= 0%) ethnic groups (Figure 1).
SNP rs4926244 resides within an intronic region near the 3′ end of CACNA1A. It is flanked 
closely by recombination events (Figure 2) and is confined to its own linkage disequilibrium 
(LD) block (Supplementary Figure 3). We did not observe association with any genetic 
marker surpassing the nominal threshold of P < 0.001 outside of this critical region (Figure 
2)24. We next performed imputation for unobserved SNPs at the CACNA1A locus on the 
basis of 1,000 Genomes cosmopolitan project data using the Phase 3 release (June 2014, see 
Methods) across the GWAS discovery collection. We were able to successfully impute 
5602 SNPs across the CACNA1A locus. However, subsequent association analysis utilizing 
the imputed SNPs did not identify additional genetic associations that surpassed the 
statistical significance of rs4926244 (Supplementary Figure 4). Notably, the most significant 
SNPs emerging from the cosmopolitan imputation analysis are intronic and are all moderate-
to-highly correlated with rs4926244 (Supplementary Table 5). None of these correlated SNP 
markers lies in strong motifs for transcription factor binding sites as identified by ENCODE. 
They also do not tag any common non-synonymous variants in CACNA1A (Supplementary 
Table 6). Haplotype association analysis assessing SNPs in a 2, 3, and 4 marker sliding 
window did not reveal evidence of association surpassing that observed for rs4926244 
(lowest haplotype P-value = 0.00021; Supplementary Table 7), and we further note that all 
but one haplotype showing evidence of association exceeding P < 0.0005 in the GWAS 
dataset contained SNP rs4926244 (Supplementary Table 7). This suggests that rs4926244 is 
likely driving the common-variant haplotype association results, and that detailed fine-
mapping of this locus using deep re-sequencing may be required. Examination of a recently 
available large-scale eQTL mapping database indicates the risk allele G at rs4926244 is 
modestly correlated with lower CACNA1A mRNA levels in peripheral blood cells (Z=−3.00, 
P=0.0027), suggesting that it may influence XFS risk through an effect on CACNA1A 
expression25. Further work will be needed to evaluate its effect in human ocular tissues.
Initial analysis of the LOXL1 locus in the GWAS discovery dataset of Japanese descent 
demonstrated strong association at rs4886776 (ORA-allele = 8.31, P = 7.37 × 10−137). The 
strength of this association vastly exceeded that of marker rs3825942 (responsible for a 
p.G153D substitution in exon 1 of LOXL1), which has been the most widely tested and 
reported SNP association prior to this analysis22. Performing the analysis after conditioning 
for the allele dosage of rs4886776 extinguished the signal of association for every other 
genetic marker within the LOXL1 locus. Conversely, conditioning the analysis for allele 
dosage at rs3825942 still resulted in genome-wide significant association at many of the 
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other LOXL1 SNPs, including rs4886776 (Supplementary Table 8). These data suggest that 
within the Japanese GWAS discovery set, the observed association at LOXL1 can be 
attributed to rs4886776 alone. We note that rs4886776 is in high LD with rs1048661 
(r2=0.98 in 1000 genomes Asians), a SNP responsible for another non-synonymous 
substitution (p.R141L) in LOXL1 but was not directly genotyped in our dataset. However, 
we were able to successfully impute rs1048661 in our GWAS discovery dataset and we 
confirmed strong association between it and XFS (ORT-allele = 8.13, P = 1.32 × 10−126). 
SNP rs1048661 has been previously reported to show strong association with XFS in 
multiple populations, although the risk allele is reversed depending on which ethnic group is 
being studied11,22. This SNP is also in LD with several other LOXL1 SNPs in potential 
transcription factor binding sites (Supplementary Table 6)26,27.
Both rs4886776 and rs3825942 are in moderate pair-wise linkage disequilibrium (r2 = 0.23). 
When we genotyped rs4886776 through the 2,628 XFS cases and 8,947 controls from Stage 
1 validation (Supplementary Table 1), we noted very strong evidence of consistent 
association in the Japanese (ORA-allele = 21.7, P = 1.54 × 10−135), leading to an 
overwhelmingly significant association in the Japanese cases and controls analyzed 
(ORA-allele = 9.87, P = 2.13 × 10−217). Strikingly in non-Japanese, the direction of the 
association was opposite to that seen in the Japanese (ORA-allele = 0.49, P = 2.35 × 10−31)
(Supplementary Figure 5). Such a scenario echoes recently reported observations for the 
reversed effect of rs3825942 on XFS risk in South Africans, and suggests that the genetic 
mechanism whereby LOXL1 exerts its effect on individual susceptibility to XFS is 
complex22. We failed to detect any evidence of statistically significant interaction between 
CACNA1A rs4926244 and the sentinel LOXL1 polymorphisms, suggesting that both loci 
impact XFS risk via distinct biological pathways.
CACNA1A encodes for the alpha 1A subunit of the type P/Q voltage-dependant calcium 
channel. Calcium channels are responsible for the transport of calcium ions across cell 
membranes and play a key role in a cell’s ability to generate and transmit electrical signals. 
Previous electron microscopy studies on human XFS eyes showed the presence of high 
calcium concentration in direct association with aggregating XFS fibrils28. In addition it is 
well known that fibrillin utilizes calcium to form stable aggregates29. Thus, it can be 
hypothesized that altered function of a calcium channel could lead to alterations of calcium 
concentrations that may facilitate the formation of XFS aggregates.
As there is a paucity of information on CACNA1A expression in the eye, we examined the 
mRNA expression profile and protein expression of CACNA1A from a variety of human 
ocular tissues and cell lines respectively (Supplementary Figure 6). CACNA1A mRNA 
expression was detected in all of the ocular tissues we studied with the exception of the optic 
nerve head (Supplementary Figure 6, panel A). Expression of different CACNA1A isoforms 
appear to be higher in human ocular tissue-derived cells than in cells of non-ocular origin 
(Supplementary Figure 6, panel B). Immunofluorescence and immunohistochemistry 
analysis was also performed on adult human eyes which showed positive immunoreactivity 
for CACNA1A in multiple human ocular tissues (Figure 3, Supplementary Figure 7 & 8). 
The distribution of CACNA1A was similar in human ocular tissues of individuals with or 
without XFS (Figure 3, Supplementary Figures 8 & 9). Positive staining and localization of 
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CACNA1A in the human eye was further corroborated by immunofluorescence microscopy 
analysis in mouse eyes. (Supplementary Figure 10). In the human eyes, we observed 
positive CACNA1A immunoreactivity in the ciliary body and iris (Figure 3). Positive 
staining of CACNA1A was also seen in the anterior lens epithelium but not in the acellular 
capsule and the cornea (Supplementary Figure 7 & 9). The optic nerve glia and vascular 
endothelial cells also showed positive immunoreactivity with CACNA1A (Supplementary 
Figure 9). In the retina, strong diffuse CACNA1A staining was seen in the photoreceptor 
inner segments (IS), inner nuclear layer (INL) and outer nuclear layer (ONL) and nerve fibre 
layer (NFL) of non XFS globes in comparison to the XFS globes where focal and patchy 
immunostaining of the IS, ONL, INL and NFL was observed. Light microscopy comparison 
of the irides in XFS eyes against non-XFS eyes showed typical XFS findings of exfoliated 
material on the posterior iris and atrophic iris pigment epithelium, as well as the possible 
atrophy of the iris dilator muscle in XFS eyes (Figure 3). Double immunofluorescence 
microscopy for CACNA1A and LOXL1 was also performed in human eyes with XFS and 
without XFS and showed co-localisation of CACNA1A and LOXL1 only in the epithelium 
of the ciliary processes. The exfoliated material in XFS eyes showed LOXL1 positive 
staining with negligible CACNA1A immunoreactivity. The ciliary body and iris smooth 
musculature had CACNA1A positive immunostaining but were negatively stained for 
LOXL1 in both XFS and non-XFS eyes (Figure 3). This observation raises the possibility 
that CACNA1A and LOXL1 contribute to XFS pathology through different mechanisms at 
different ocular sites.
In summary, we have identified a susceptibility locus mapping to CACNA1A using a three-
staged GWAS study design. Further investigation of this locus is now warranted to uncover 
the mechanisms via which CACNA1A affects individual susceptibility to XFS.
Online Methods
Patient recruitment
Detailed information on all XFS sample collections can be found in Supplementary note. All 
patients and controls were enrolled into the study following informed consent and ethical 
approval from the relevant national and regional institutional review boards for each sample 
collection. DNA was extracted from patient blood samples using standard, well-described 
laboratory procedures for genetic analysis.
Genotyping
For the GWAS discovery stage, genome-wide genotyping was performed using the Illumina 
OmniExpress beadchips, following manufacturer’s instructions (see URLs). For validation 
(Stage 1), genotyping was performed using the Sequenom MassArray platform (see URLs). 
For replication (Stage 2), genotyping was performed using Applied Biosystems Taqman 
probes (see URLs) for India, Germany, Italy, China, Iran, Poland, and Argentina. The 
Australian replication collection had GWAS genotyping on all cases and controls using 
Illumina genome-wide arrays, and CACNA1A rs4926244 was directly genotyped from the 
GWAS arrays. We perform cross-platform concordance checks and verify >99.9% 
concordance of genotypes for SNP markers of interest reported here (e.g. rs4926244).
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Statistical analysis
Stringent quality control filters were used to remove poorly performing samples and SNP 
markers in both the GWAS discovery and validation phases. The SNPs with call rates of less 
than 95%, minor allele frequency of less than 1 percent, or showing significant deviation 
from Hardy-Weinberg Equilibrium (P-value for deviation < 1 × 10−6) were removed from 
further statistical analysis. Likewise, samples with an overall genotyping success rate of less 
than 95% were removed from further analysis. The remaining samples were then subjected 
to biological relationship verification by using the principle of variability in allele sharing. 
Identity-by-state information was derived using PLINK (see URLs). For those pairs of 
individuals who showed evidence of cryptic relatedness (possibly either due to duplicated or 
biologically related samples), we removed the sample with the lower call rate before 
performing principal component (PC) analysis. PC analysis was undertaken to account for 
spurious associations resulting from ancestral differences of individual SNPs and PC plots 
were performed using the R statistical program package (see URLs). For the GWAS 
discovery stage, all XFS cases had genetically matched controls as visualized spatially on 
PC analysis (Supplementary Figures 11a and 11b). A total of 581,023 autosomal SNPs 
passed quality filters for call rate and minor allele frequency (see Methods) and were 
included for further analysis. Genotypes were contrasted between XFS cases and controls 
using logistic regression, with adjustments for the top 6 principal components of genetic 
ancestry to further minimize confounding due to cryptic population stratification. We did not 
observe any evidence of genomic inflation (λgc = 1; Supplementary Figure 12), suggesting 
that the association results were not confounded by external artefacts such as genetic 
mismatch between cases and controls. Crucially, we did not observe any deviation or 
dispersion of test statistics when patients with XFS without glaucoma were compared to 
patients with exfoliation glaucoma (Supplementary Figure 13). This suggests that our 
primary analysis approach in combining all XFS patients into an overall case group is valid.
For the GWAS discovery, validation, and replication stages, analysis of association with 
XFS disease status was carried out using allele-based score tests (1 degree of freedom), 
which models additive effects of the minor allele on disease risk. For the GWAS discovery 
stage, we incorporated the top six principal components of genetic stratification into the 
logistic regression model while performing the analysis for association to minimize the 
effect of residual population stratification. As the follow up validation (Stage 1) and 
replication (Stage 2) phases only tested a limited number of genetic markers, we were 
unable to adjust for population stratification in these follow up sample collections. However, 
association tests were performed by site to minimize population stratification and then 
subsequently combined in meta-analysis as described below. All P-values reported here are 
two-tailed.
Meta-analysis was conducted using inverse variance weights for each sample collection, 
which calculates an overall Z-statistic, its corresponding P-value, and accompanying odds 
ratios for each SNP analyzed. The meta-analysis is performed under the fixed effects 
model30. Analysis of linkage disequilibrium was performed using the R software package 
(version 2.9.0) and associated rmeta and RColorBrewer analytical packages.
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Genotype Imputation
Fine-scale imputation at CACNA1A was performed using all 1,484 XFS cases and 1,188 
controls passing the standard GWAS QC checks. The imputation and phasing of genotypes 
were carried out using IMPUTE2 (see URLs) with cosmopolitan population haplotypes 
based on data from 2535 individuals from 26 distinct populations around the world obtained 
from the 1000 Genomes project Phase 3 (Jun 2014) release for reference panel construction. 
Imputed genotypes were called with an impute probability threshold of 0.90 with all other 
genotypes classified as missing. Additional quality control filters were applied to remove 
SNPs with a call rate of < 99% should the SNP have a minor allele frequency (MAF) below 
5% in either cases or controls. For common SNPS with MAF above 5%, the filtering criteria 
were set at less than 95% call rate.
Power calculations
All statistical power calculations were performed as previously described31. We present 
these power calculations for each of the following conditions; a) GWAS discovery stage 
only, b) GWAS discovery plus stage 1 validation, and c) GWAS discovery plus stage 1 
validation plus stage 2 replication (Supplementary Table 9).
Expression analysis
RT-PCR in human ocular tissues: Multiple transcript variants encoding different isoforms 
have been found for CACNA1A. Here we assessed for the presence of either of the two 
major transcripts known for CACNA1A, which encode 2506 and 2261 amino acid isoforms, 
CaV2.1 variant-1 and 2 (CaV2.1_V2 and CaV2.1_V1, NCBI Reference Sequences: 
NM_001127222.1/NP_001120694.1 and NM_001127221.1/NP_001120693.1). All of the 
known critical regulatory elements of the CaV2.1 C-terminal tail are included in both 
variants, but the polyQ domain is excluded from the short-tail CaV2.1_V1 isoform32. We 
utilized 5 pairs of primers spread across and common to both transcripts to assess the 
presence of either transcript in eye tissues (Supplementary Table 10) CACNA1A transcript 
expression was assessed by semi quantitative reverse transcription PCR (RT-PCR) using the 
above mentioned CACNA1A specific primers on total RNA extracted from a variety of 
ocular tissues (anterior sclera, cornea, iris, trabecular meshwork, lens capsule, retina, 
choroid, optic nerve head and optic nerve) with TRIzol® Reagent (Invitrogen, Carlsbad, 
California) in accordance with the manufacturer’s protocol. First-strand cDNA synthesis 
was performed with SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, 
Carlsbad, California). Semi quantitative RT-PCR was performed according to 
manufacturer’s protocol, with the SYBR® Green Master Mix (Invitrogen, Carlsbad, 
California) using the above CACNA1A primers. RT-PCR products were separated on a 2% 
agarose gel and visualized by ethidium bromide staining. The ubiquitously expressed beta-
actin (ACTB) gene was amplified using specific primers (Supplementary Table 10) and used 
as amplification and normalizing control.
Western Blotting
Cell lines obtained from American Type Culture Collection (Manassas, VA, USA) were the 
human retinal pigment epithelial cell line (APRE19), human cervical adenocarcinoma cell 
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line (Hela S), human breast adenocarcinoma cell line (MCF7), and human embryonic kidney 
epithelial cell line (HEK 293). Human nonpigmented ciliary epithelial cell line (NPCE) is a 
kind gift from Prof. Miguel Coca-Prados from Yale School of Medicine. Human Trabecular 
Meshwork cell line (HTM) was purchased from PromoCell GmbH (Heidelberg, Germany). 
Cell lysates were obtained by lysing individual cell lines with lysis buffer (50 mM Tris-HCl, 
pH 8, 150 mM NaCl, 1.0% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 0.2 mM NaVO4, 
10 mM NaF, 0.4 mM EDTA, and 10% glycerol). SDS-PAGE resolved proteins were 
transferred to Hybond-C Extra nitrocellulose membranes (Amersham Life Science Inc., 
Arlington Heights, IL, USA). Membranes were blocked by 5% nonfat milk, 0.1% Tween 20 
in Tris-buffered saline (20 mM Tris-HCl, pH 7.6, 150 mM NaCl) for 1 h before incubation 
with CACNA1A (1:1000) from Abcam Inc. (Cambridge, MA, USA), Actin-horseradish 
peroxidase (HRP) (1:50000) from Santa Cruz Biotechnology (Dallas, TX, USA). Blocking 
and blotting of antibodies were performed in 10% horse serum (Sigma-Aldrich Corp., St. 
Louis, MO, USA), 0.1% Tween 20 in phosphate-buffered saline for 1 h. The bound primary 
antibodies were detected by horseradish peroxidase-conjugated secondary antibodies (GE 
Healthcare Biosciences, Pittsburgh, PA, USA), and visualized by Luminata Forte Western 
HRP substrate (Millipore, Bedford, MA, USA).
Immunofluorescence Confocal Microscopy
Immunofluorescence confocal microscopy was performed on antigen retrieved 4μm paraffin 
sections. Blocking of tissue sections was performed with blocking buffer (10% FBS, 0.1% 
PBS-Tween; 1x pen/strep) for 1 hour at RT. CACNA1A (Abcam Inc., Catalog#: Ab81011 
from Abcam) and LOXL1 (ABNOVA, Catalog # : H00004016-B01P from Abnova) 
antibodies were diluted at 1:300 ratio with blocking buffer and incubated overnight at 4°C. 
Secondary FITC (1:300) or Cy3 (1:300) labeled anti-mouse or anti-rabbit antibodies 
(Jackson Laboratories, Westgrove, PA, USA) were also diluted in blocking buffer and 
incubated at RT for 1 hour followed by application of Vectashield with 4′,6-diamidino-2-
phenyl-indole (DAPI) (Vector Laboratories, Burlingame, CA, USA). Cover-slips were then 
used to overlay the sections and stored in the dark at 4°C until viewing with Olympus 
Fluoview 1000 confocal microscope (Olympus Optical Co. Ltd., Tokyo, Japan).
Immunohistochemistry
A total of 7 archival enucleated globes were retrieved for IHC analysis with CACNA1A 
(1:50) (Abcam Inc., Cambridge, MA, USA) and LOXL1 (1:50) (ABNOVA, Taipei, Taiwan) 
antibodies. Three human eye globes from Saudi Arabia and 1 from Denmark with a history 
of advanced XFS were obtained courtesy of Deepak Edward (KKESH, Riyadh Saudi 
Arabia) and Steffen Heegaard (University of Copenhagen, Denmark) respectively. Three 
additional eyes from Singapore (SGH-SNEC Ophthalmic pathology service, SGH 
Pathology) that were exenterated for other external pathological diagnoses that did not 
involve the globe were used as non-XFS controls. Immunohistochemistry (IHC) analysis 
was performed according to our previously published protocol33. In brief, paraffin sections 
were cut at 4μm and placed on coated slides. Immunohistochemistry was performed using 
the Leica Bond Polymer Refine detection kit DS9800 (Leica Microsystems GmbH, Wetzlar, 
#Members of consortia and study groups are listed in the Supplementary Note.
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Germany). Slides were heated for 20 minutes at 60°C and then loaded onto the Leica Bond 
III autostainer for immunohistochemical staining. Staining on the autostainer consisted of 
dewaxing, antigen retrieval using Leica Bond ER2 solution for 20mins at 100°C, antibody 
incubation for 20minutes at room temperature followed by staining using the Bond polymer 
refine kit. Polymeric alkaline phosphatase-AP linker antibody conjugate system (Vision 
Biosystems, Norwell, MA, USA) and counterstaining with haematoxylin were applied for 
visualization, after which the slides were dehydrated and cover-slipped.
Immunofluorescence confocal microscopy in mice
C57BL/6J and B6(Cg)-Tyrc-2J/J mice were obtained from The Jackson Laboratory 
production facility. Mice were housed with a 14-hour-light/10-hour-dark cycle, under the 
same conditions as previously described34. All experiments were performed in compliance 
with the ARVO statement for use of animals in ophthalmic and vision research and 
approved by The Jackson Laboratory Animal Care and Use Committee. Adult mice were 
deeply anesthetized and perfused with 1X phosphate buffered saline (PBS) and eyes were 
enucleated. Fresh tissue was frozen in optimal cutting temperature (OCT) compound frozen 
by liquid nitrogen cooled isopentane and stored at −80°C or eyes were fixed overnight in 4% 
paraformaldehyde. Fixed eyes were cyroprotected in 30% sucrose, rinsed in 1X PBS and 
frozen in OCT for sectioning. Eyes were cut into 12 μm sections. Primary antibodies used to 
stain sections included anti-CACNA1A (1:500, Millipore, Billerica, MA, USA), anti-
Endomucin (EMCN; 1:500; eBioscience, San Diego, CA, USA), and anti-smooth muscle 
Actin (ACTA2; 1:500; Abcam, Cambridge, MA, USA). Alexafluor secondary antibodies 
from Invitrogen were used to label by immunofluorescence. Sections were desiccated, 
washed in 1X PBS with 0.5% Triton and incubated with primary antibodies overnight. 
Sections were subsequently washed in 1X PBS and incubated with secondary antibodies for 
60 minutes. DAPI was used to stain nuclei. For each experiment, at least four sections from 
four eyes were assessed. Microscopy was performed on the Axio Imager (Zeiss).
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Figure 1. 
Forest plot for the associations between CACNA1A rs4926244 and Exfoliation syndrome in 
discovery and follow up case-control collections. The black lines denote the 95% confidence 
intervals of the odds ratio for each collection. The diamonds denote summary results for the 
GWAS, Validation and Replication stages (blue), as well as the GWAS and Validation 
meta-analysis, and meta-analysis of data from all collections (red). Asian and European 
ethnic summaries are in black diamonds.
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Figure 2. 
Regional association and recombination rate plot for the CACNA1A rs4926244 locus. The 
left y axis represents –log10 P values for association with exfoliation syndrome and the right 
y axis represents the recombination rate. The x axis represents base-pair positions along the 
chromosome (human genome Build 37). The diamonds denote the summary of each 
experimental stage, a) for the GWAS discovery, b) for the meta-analysis between GWAS 
discovery and validation stages, and c) for the meta-analysis between GWAS discovery, 
validation, and replication stages.
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Figure 3. 
CACNA1A and LOXL1 protein expression and light microscopic analysis in XFS and non-
XFS control eyes. Immunolocalisation of CACNA1A in human non-XFS and XFS globes 
show CACNA1A positive immunoreactivity in the smooth musculature of the ciliary body 
(CB) and pigmented and non-pigmented ciliary process (CP) epithelium with variable 
staining in the zonules (Panels a to c: CACNA1A immunofluorescence (IF) panel; 
CACNA1A immunohistochemical (IHC) panel, 40x; zonules, white and black arrows; 
exfoliated material, green asterix). In contrast, LOXL1 immunoreactivity is present only in 
the exfoliated material and the CP epithelium, (LOXL1 IF panel; zonules, white arrows). 
Double immunofluorecence analysis shows colocalisation of CACNA1A and LOXL1 within 
the non-pigmented and pigmented epithelium of the CP but not in the CB smooth muscles or 
the zonules (IF overlay panel; zonules, white arrows). Light microscopy comparison of non-
XFS and XFS irides show the typical XFS findings of exfoliated material (green asterix) on 
the posterior iris and atrophic iris pigment epithelium with possible atrophy of the iris dilator 
muscle (blue arrowheads) in XFS irides. The sphincter pupillae in both non-XFS and XFS 
shows negligible differences (H&E panels). CACNA1A positive immunoreactivity is also 
seen in the anterior iris border, iris stromal cells, the iris dilator (blue arrowheads, H&E and 
IHC panels) and sphincter muscles as well as the iris pigmented epithelium in both XFS and 
Non-XFS irides (Panel d & e: CACNA1A IF and CACNA1A IHC panels). Stromal cells are 
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highlighted by the blue circles. For CACNA1A, LOXL1, and overlay panels a) through to 
d), each unit on the scale bar represents 100 μm. For CACNA1A IHC panels a) to d), each 
unit on the scale bar represents 50 μm. For panel e) hematoxylin & eosin non-XFS as well as 
hematoxylin & eosin XFS1, each unit on the scale bar represents 200 μm. For panel e) 
CACNA1A IHC XFS2 as well as CACNA1A IHC non-XFS, each unit on the scale bar 
represents 25 μm.
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